Get the Stockscreener App
72.14
0.37%
0.265
Avidity Biosciences Inc stock is traded at $72.14, with a volume of 2.94M.
It is up +0.37% in the last 24 hours and up +1.81% over the past month.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
See More
Previous Close:
$71.87
Open:
$71.96
24h Volume:
2.94M
Relative Volume:
0.64
Market Cap:
$10.87B
Revenue:
$10.73M
Net Income/Loss:
$-455.74M
P/E Ratio:
-20.28
EPS:
-3.5569
Net Cash Flow:
$-502.70M
1W Performance:
+0.75%
1M Performance:
+1.81%
6M Performance:
+146.03%
1Y Performance:
+134.97%
1-Day Range:
$71.96
$72.20
1-Week Range:
$71.52
$72.20
52-Week Range:
$21.51
$72.20
Avidity Biosciences Inc Stock (RNA) Company Profile
Name
Avidity Biosciences Inc
Sector
Industry
Phone
858-401-7900
Address
3020 CALLAN ROAD, SAN DIEGO, CA
Compare RNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
72.14 | 10.83B | 10.73M | -455.74M | -502.70M | -3.5569 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.38 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.71 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.04 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
847.05 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.55 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Roth Capital | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Jun-24-25 | Initiated | Bernstein | Outperform |
| Jun-17-25 | Initiated | Wolfe Research | Outperform |
| Jun-11-25 | Initiated | Raymond James | Strong Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-20-24 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-24 | Initiated | Goldman | Buy |
| Aug-28-24 | Initiated | Barclays | Overweight |
| May-03-24 | Initiated | BofA Securities | Buy |
| Mar-14-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-22-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Strong Buy |
| Sep-07-21 | Initiated | Evercore ISI | Outperform |
| Jun-17-21 | Initiated | Needham | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | SVB Leerink | Outperform |
| Jul-07-20 | Initiated | Wells Fargo | Overweight |
View All
Avidity Biosciences Inc Stock (RNA) Latest News
Avidity Biosciences (NASDAQ:RNA) Lowered to Hold Rating by Evercore ISI - MarketBeat
Will Avidity Biosciences Inc. stock gain from strong economy2025 Institutional Moves & Technical Buy Zone Confirmation - DonanımHaber
Avidity reports FTC granted request for early termination of HSR waiting period - MSN
Novartis-Avidity Biosciences deal gets early clearance in US - MLex
Evercore ISI Downgrades Avidity Biosciences to In Line From Outperform, Adjusts Price Target to $72 From $65 - marketscreener.com
Avidity Biosciences Receives FTC Clearance for Novartis Merger - TipRanks
Avidity Biosciences (NASDAQ:RNA) Sets New 52-Week HighHere's Why - MarketBeat
Is Avidity Biosciences Inc. stock resilient to inflation2025 Key Highlights & Real-Time Price Movement Reports - Bollywood Helpline
Mirador Capital Partners LP Purchases 22,666 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences (NASDAQ: RNA) advances Novartis merger and revises executive pay - Stock Titan
Top 2 Health Care Stocks That May Keep You Up At Night In December - Benzinga
Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity - MSN
Frazier Life Sciences Management L.P. Has $17.75 Million Stock Holdings in Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Reaches New 52-Week HighWhat's Next? - MarketBeat
EcoR1 Capital LLC Sells 57,576 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences stock hits all-time high at 71.81 USD By Investing.com - Investing.com Australia
Avidity Biosciences stock hits all-time high at 71.81 USD - Investing.com
Aug Closing: Is Avidity Biosciences Inc stock vulnerable to regulatory risksTrade Performance Summary & Growth-Oriented Investment Plans - moha.gov.vn
Avoiding Lag: Real-Time Signals in (RNA) Movement - news.stocktradersdaily.com
Avidity Biosciences (RNA) Soars 42% on $12-Billion Novartis Merger - MSN
Assessing Avidity Biosciences (RNA) Valuation After a 130% Year-to-Date Share Price Surge - Yahoo Finance
Dyne stock upgraded at Oppenheimer (DYN:NASDAQ) - Seeking Alpha
Dyne Therapeutics' Biggest Catalyst is Avidity Biosciences' DM1 Readout in H2 2026, Oppenheimer Says - marketscreener.com
Norges Bank Makes New Investment in Avidity Biosciences, Inc. $RNA - MarketBeat
Franklin Resources Inc. Sells 29,465 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
JPMorgan Chase & Co. Buys 139,473 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences stock hits all-time high at 71.78 USD By Investing.com - Investing.com South Africa
Avidity Biosciences stock hits all-time high at 71.78 USD - Investing.com
Why Avidity Biosciences Inc. stock could benefit from AI revolution2025 Breakouts & Breakdowns & Free Expert Approved Momentum Trade Ideas - Newser
Avidity Biosciences, Inc. (RNA): A Bull Case Theory - Finviz
Schroder Investment Management Group Raises Stake in Avidity Biosciences, Inc. $RNA - MarketBeat
How Avidity Biosciences Inc. stock reacts to Fed rate cutsEarnings Overview Summary & AI Enhanced Trade Execution Alerts - Newser
Avidity Biosciences, Inc. $RNA Shares Sold by Steward Partners Investment Advisory LLC - MarketBeat
Avidity Biosciences, Inc. $RNA Shares Sold by Prudential Financial Inc. - MarketBeat
Will Avidity Biosciences Inc. stock outperform Dow Jones indexMarket Growth Report & Detailed Earnings Play Alerts - Newser
Creative Planning Grows Stock Holdings in Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44 (PR Newswire) - Aktiellt
Discipline and Rules-Based Execution in RNA Response - news.stocktradersdaily.com
Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 (PR Newswire) - Aktiellt
Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society (PR Newswire) - Aktiellt
Update Recap: Can Avidity Biosciences Inc. stock sustain free cash flow growth2025 Risk Factors & Reliable Entry Point Alerts - BỘ NỘI VỤ
What analysts say about Avidity Biosciences Inc stockSwing Trading Watchlist & Investment Timing Techniques - earlytimes.in
SG Americas Securities LLC Raises Holdings in Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights (PR Newswire) - Aktiellt
Avidity Biosciences, Inc. $RNA Shares Sold by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Dyne Therapeutics Stock Soars After Rival Avidity Biosciences Gets Acquired By Novartis - MSN
Avidity Played Hardball to Land Favorable Terms in $12B Novartis Deal - BioSpace
Avidity Biosciences stock hits all-time high at 71.1 USD By Investing.com - Investing.com Nigeria
Avidity Biosciences stock hits all-time high at 71.1 USD - Investing.com
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Ensign Peak Advisors Inc Purchases 200,836 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences Inc Stock (RNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Avidity Biosciences Inc Stock (RNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hughes Steven George | Chief Medical Officer |
Oct 22 '25 |
Sale |
47.54 |
2,209 |
105,015 |
38,867 |
| McCarthy Teresa | Chief Human Resources Officer |
Oct 15 '25 |
Option Exercise |
22.34 |
20,000 |
446,800 |
117,130 |
| McCarthy Teresa | Chief Human Resources Officer |
Oct 15 '25 |
Sale |
50.15 |
20,000 |
1,003,058 |
97,130 |
| Mosbrooker Eric | Chief Commercial Officer |
Oct 03 '25 |
Option Exercise |
9.05 |
6,562 |
59,386 |
61,562 |
| Mosbrooker Eric | Chief Commercial Officer |
Oct 03 '25 |
Sale |
45.38 |
6,562 |
297,771 |
55,000 |
| Hughes Steven George | Chief Medical Officer |
Sep 22 '25 |
Option Exercise |
10.16 |
2,208 |
22,433 |
41,075 |
| Hughes Steven George | Chief Medical Officer |
Sep 22 '25 |
Sale |
40.58 |
2,208 |
89,601 |
38,867 |
| McCarthy Teresa | Chief Human Resources Officer |
Sep 15 '25 |
Option Exercise |
22.34 |
15,000 |
335,100 |
112,130 |
| McCarthy Teresa | Chief Human Resources Officer |
Sep 15 '25 |
Sale |
41.41 |
15,000 |
621,142 |
97,130 |
| Hughes Steven George | Chief Medical Officer |
Sep 15 '25 |
Option Exercise |
6.57 |
1,542 |
10,131 |
40,409 |
0.31%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):